Compare General Dynamics Corporation (GD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Summit Therapeutics Inc — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: General Dynamics Corporation is far larger — about 6.5× Summit Therapeutics Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Summit Therapeutics Inc for 16 Days on average.
| GD | SMMT | |
|---|---|---|
Market Cap | $89.26B | $13.71B |
Volume | 1,496,273 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $395.97 | $26.38 |
52-Week Low | $312.53 | $12.43 |
Typical Hold Time | 85 Days | 16 Days |
Enterprise Value | $94.40B | $13.04B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, up 1.0% with strong fundamental performance including three consecutive quarterly earnings beats and robust 2025 revenue of $52.55 billion. The stock shows bearish technical signals despite positive analyst sentiment with a $420.57 consensus price target representing 27.5% upside potential. Defense sector tailwinds from Pentagon spending and dividend stability support the investment case.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.12, P/S 1.65) and strong profitability metrics (ROE 17.8%, net margin 8.18%). Key risks include defense budget volatility and technical weakness, but the company's consistent earnings performance and analyst support suggest potential for medium-term appreciation.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
